Who Paid My Doc
Saifuddin Mama
Obstetrics & Gynecology Marlton, NJ Medical Doctor
NPI 1811906878 CMS profile 354858
127 N Church Road, Suite 200 Cooper Faculty Obgyn, Marlton, NJ 08053
General payments
$20,530
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$30,117
Through program year 2025, Saifuddin Mama of Marlton, NJ is reported in the CMS Open Payments database as having received $20,530 across 66 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $30,117 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $7,775 | 12 | |
| 2024 | General | $263 | 3 | |
| 2023 | General | $222 | 6 | |
| 2022 | General | $5,908 | 16 | |
| 2021 | General | $5,698 | 10 | |
| 2020 | General | $58 | 4 | |
| 2019 | General | $605 | 15 |
Beside peers
- Saifuddin Mama
- Obstetrics & Gynecology median
- Middle half of Obstetrics & Gynecology
- National median
In program year 2025, general payments to Saifuddin Mama were reported at $7,775. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.
Show as a table
| Year | Saifuddin Mama | Obstetrics & Gynecology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $605 | $172 | $62–$391 | $163 |
| 2020 | $58 | $94 | $36–$222 | $114 |
| 2021 | $5,698 | $136 | $42–$369 | $132 |
| 2022 | $5,908 | $160 | $50–$433 | $149 |
| 2023 | $222 | $169 | $56–$423 | $160 |
| 2024 | $263 | $152 | $50–$371 | $164 |
| 2025 | $7,775 | $158 | $51–$401 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 12 drugsPart D claims
473
Drug cost
$78,802
Branded share of claims
31.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Gemtesa Vibegron | Brand | 44 | $28,597 | |
| Myrbetriq Mirabegron | Brand | 26 | $22,310 | |
| Estradiol | Generic | 218 | $15,552 | |
| Premarin Estrogens, Conjugated | Brand | 15 | $7,348 | |
| Bethanechol Chloride | Generic | 23 | $1,820 | |
| Norethindrone Acetate | Generic | 36 | $1,075 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 27 | $604 | |
| Tolterodine Tartrate Er Tolterodine Tartrate | Brand | 11 | $516 | |
| Tamsulosin Hcl | Generic | 27 | $423 | |
| Oxybutynin Chloride Er Oxybutynin Chloride | Brand | 14 | $281 |
The 10 drugs with the highest cost, of 12 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 41 billing codesPaid by Medicare
$37,660
Medicare patients
98
Services billed
307
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 66% | |
| Arthritis | 61% | |
| Osteoporosis | 28% | |
| Depression | 26% | |
| Diabetes | 23% | |
| Cancer | 20% | |
| Ischemic heart disease | 18% | |
| Chronic kidney disease | 17% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
66 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Obstetrics & Gynecology in New Jersey
Practitioners in the same specialty and state, ranked by reported value.
All Obstetrics & Gynecology
Everyone recorded under this specialty, nationwide.
Doctors in New Jersey
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.